Genetics & heredity

Gene Therapy Pioneers Win $3 Million Breakthrough Prize

Is gene therapy being killed by broken economics or accelerated by unstoppable market-driven innovation?

Published 4 days ago

Gene Therapy Pioneers Win $3 Million Breakthrough Prize

story

Above: Dr. Albert Maguire and Dr. Jean Bennett at the 12th Breakthrough Prize Ceremony on April 18 in Santa Monica, California. Image credit: Taylor Hill/FilmMagic/Getty Images

The Spin

Techno-optimist narrative

Gene therapy is entering its most transformative era yet, with AI-designed proteins, precise CRISPR editing and approved treatments for retinal disorders, spinal muscular atrophy and blood cancers proving the science works. Viral and non-viral delivery systems keep improving in safety and efficiency, expanding the range of treatable diseases fast. Market-driven biotech innovation is accelerating cures at a pace no government program could match.

International Journal Pharmaceutical Sciences

Mgoes on X

Techno-skeptic narrative

Gene therapy's promise is being strangled by broken economics and political neglect. Per-patient costs can run into seven figures, and companies like Prime Medicine are already halting work on successful treatments because the business model doesn't hold up. Only a publicly funded health system treating gene therapy like dialysis or transplants — a collective service, not a market commodity — can turn lab breakthroughs into medicine for everyone.

Guardian

Metaculus Prediction

There is a 25% chance the U.S., U.K. or E.U. will approve a gene editing therapy for a new condition during 2026, according to the Metaculus prediction community.